Why the study?
Does repaglinide or glibenclamide reduce meal-induced platelet activation and endothelial markers in patients with Type 2 diabetes mellitus?
Population
15 patients with Type 2 diabetes mellitus, and 15 non-diabetic control subjects matched for sex, age, and BMI.
Comparison
Repaglinide for 6 weeks vs Glibenclamide for 6 weeks, and baseline without…
Design
RCT, randomized cross-over, open
Follow-up
6 weeks per treatment period
Authors
Loading...
Neither repaglinide nor glibenclamide reduces meal-induced platelet activation in T2DM; challenges postprandial expectations while confirming fasting marker reductions with repaglinide.
Does repaglinide or glibenclamide reduce meal-induced platelet activation and endothelial markers in patients with Type 2 diabetes mellitus?
Repaglinide, but not glibenclamide, attenuates fasting platelet and endothelial activity in Type 2 diabetes, though neither prevents postprandial platelet activation.
Yngen et al. (2005) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: